Neratinib enhances trastuzumab emtansine trafficking and antitumor activity in breast cancer models
Purpose The efficacy of trastuzumab emtansine (T-DM1) relies on HER2 binding, internalization, intracellular processing, and payload delivery. We investigated how neratinib and tucatinib differentially affect T-DM1 trafficking and antitumor activity in breast cancer models. Methods HER2-expressing breast cancer cells were treated with T-DM1 alone or in combination with neratinib or tucatinib, and cell viability was assessed by CCK-8 assay. pHrodo-labeled T-DM1 was used to quantify acidification-associated intracellular accumulation. HER2 phosphorylation and HER2-associated ubiquitination were examined by immunoblotting and immunoprecipitation. Antitumor activity was evaluated in HCC1954 orthotopic xenografts. Results Neratinib enhanced T-DM1-mediated viability reduction from 51.7% to 31.0% in SK-BR-3 cells and from 37.4% to 19.3% in HCC1954 cells. In contrast, tucatinib did not significantly augment T-DM1 activity. Neratinib increased the pHrodo-T-DM1 fluorescence index and HER2-associated ubiquitin signal, while both kinase inhibitors reduced HER2 phosphorylation. Dynasore, an inhibitor of dynamin-dependent endocytosis, reduced pHrodo fluorescence and partially reversed the observed viability loss. In cells with lower ERBB2 transcript expression, the combination effects were modest. In xenografts, T-DM1 combined with neratinib significantly reduced tumor growth compared to T-DM1 alone and was associated with reduced HER2-pathway phosphorylation and increased caspase-3 cleavage. Conclusion We demonstrate that neratinib may potentiate T-DM1 activity, which is associated with increased accumulation in acidic compartments and increased HER2-associated ubiquitination. These findings support further evaluation of neratinib as a combination partner with T-DM1, particularly regarding productive payload delivery and treatment scheduling.
Authors
- Ming‐Jen Chen (ORCID: https://orcid.org/0000-0001-5849-4259)
- Shao-Chiang Chang
- Meng-Ching Yeh
- Yuan-Ching Chang
- Shih-Ping Cheng
Institutions
- Mackay Memorial Hospital (TW)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-19
- DOI
- https://doi.org/10.21203/rs.3.rs-11496490/v1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- preprint